NBIX
Neurocrine Biosciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$155.64
−1.71%Margins
Gross margin
98.0%
EBITDA margin
27.2%
EBIT margin
23.4%
Net margin
20.9%
FCF margin
25.8%
19.1%
Return on equity
13.2%
Return on assets
19.3%
Return on invested capital
0.66x
Asset turnover
$898.1M
Cash from operations
$3.83
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026